Literature DB >> 32923858

Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.

Ciara Nugent1, Wentian Guo2, Peter Müller1, Yuan Ji3.   

Abstract

We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about subpopulations with significantly distinct treatment effects. The discussion mainly focuses on inference for a benefiting subpopulation, that is, a characterization of a group of patients who benefit from the treatment under consideration more than the overall population. We introduce alternative approaches and demonstrate them with a small simulation study. Then, we turn to clinical trial designs. When the selection of the interesting subpopulation is carried out as the trial proceeds, the design becomes an adaptive clinical trial design, using subgroup analysis to inform the randomization and assignment of treatments to patients. We briefly review some related designs. There are a variety of approaches to Bayesian subgroup analysis. Practitioners should consider the type of subpopulations in which they are interested and choose their methods accordingly. We demonstrate how subgroup analysis can be carried out by different Bayesian methods and discuss how they identify slightly different subpopulations.
© 2019 by American Society of Clinical Oncology.

Entities:  

Year:  2019        PMID: 32923858      PMCID: PMC7446414          DOI: 10.1200/PO.19.00003

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  24 in total

1.  Using Bayesian modeling in frequentist adaptive enrichment designs.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

2.  Adaptive enrichment designs for clinical trials.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2013-03-21       Impact factor: 5.899

3.  Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.

Authors:  Zhiwei Zhang; Ruizhe Chen; Guoxing Soon; Hui Zhang
Journal:  Stat Med       Date:  2017-09-26       Impact factor: 2.373

4.  A subgroup cluster-based Bayesian adaptive design for precision medicine.

Authors:  Wentian Guo; Yuan Ji; Daniel V T Catenacci
Journal:  Biometrics       Date:  2016-10-24       Impact factor: 2.571

5.  Bayesian population finding with biomarkers in a randomized clinical trial.

Authors:  Satoshi Morita; Peter Müller
Journal:  Biometrics       Date:  2017-03-03       Impact factor: 2.571

6.  A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

Authors:  M Martín; A Chan; L Dirix; J O'Shaughnessy; R Hegg; A Manikhas; M Shtivelband; P Krivorotko; N Batista López; M Campone; M Ruiz Borrego; Q J Khan; J T Beck; M Ramos Vázquez; P Urban; S Goteti; E Di Tomaso; C Massacesi; S Delaloge
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

7.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.

Authors:  Werner Brannath; Emmanuel Zuber; Michael Branson; Frank Bretz; Paul Gallo; Martin Posch; Amy Racine-Poon
Journal:  Stat Med       Date:  2009-05-01       Impact factor: 2.373

8.  A conditional error function approach for subgroup selection in adaptive clinical trials.

Authors:  T Friede; N Parsons; N Stallard
Journal:  Stat Med       Date:  2012-08-03       Impact factor: 2.373

9.  Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.

Authors:  Patrick M Schnell; Peter Müller; Qi Tang; Bradley P Carlin
Journal:  Clin Trials       Date:  2017-10-16       Impact factor: 2.486

10.  Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.

Authors:  Kelly Claire Simon; Samuel Tideman; Laura Hillman; Rebekah Lai; Raman Jathar; Yuan Ji; Stuart Bergman-Bock; James Castle; Tiffani Franada; Thomas Freedom; Revital Marcus; Angela Mark; Steven Meyers; Susan Rubin; Irene Semenov; Chad Yucus; Anna Pham; Lisette Garduno; Monika Szela; Roberta Frigerio; Demetrius M Maraganore
Journal:  JAMIA Open       Date:  2018-06-11
View more
  2 in total

1.  A permutation procedure to detect heterogeneous treatment effects in randomized clinical trials while controlling the type I error rate.

Authors:  Jack M Wolf; Joseph S Koopmeiners; David M Vock
Journal:  Clin Trials       Date:  2022-05-09       Impact factor: 2.599

2.  Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.

Authors:  Yoon-Koo Kang; Satoshi Morita; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Hiroki Sameshima; Li-Tzong Chen; Narikazu Boku
Journal:  Gastric Cancer       Date:  2021-09-04       Impact factor: 7.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.